Company intelligence / Profile preview

Lincbiotech

Santiago de Compostela, Galicia, Spainlincbiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lincbiotech develops innovative diagnostic and therapeutic tools focused on high-prevalence neurological diseases, especially stroke and Alzheimer’s. Their flagship products include the Minerva clinical decision support system to aid clinicians managing stroke patients, next-generation monoclonal antibodies targeting aberrant Tau species relevant to Alzheimer's pathology, and a novel ELISA kit enabling early detection of misfolded proteins in cerebrospinal fluid. The company aims to improve prognosis through earlier diagnosis and enhanced patient management.

Therapeutic areas: Neurology
Modalities: Monoclonal antibodies (mAbs)ELISA diagnostic kitsClinical decision support systems (CDSS)
Industry: Biotech

Drug pipeline

1 asset

Lincbiotech anti-aberrant tau monoclonal antibody

Preclinical

Beyond the preview

Go deeper on Lincbiotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lincbiotech.

Explore the full profile